ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) study: safety, toxicity and immunological effects of peritumorally delivered immunotherapy in early-stage cervical cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505968-11-00

Acronym

14244

Enrollment

Registered

2024-02-22

Start date

2024-10-15

Completion date

Unknown

Last updated

2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026